Ebronucimab vs SAL003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ebronucimab
Marketed by Hubei Jumpcan Pharmaceutical and partners
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Reported efficacy
Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)
Result source: NCT05255094
SAL003
Developed by Shenzhen Salubris Pharmaceuticals
NCT07253584 · Phase 3 · completed
The trial randomized 720 participants to SAL003 or placebo while maintaining quadruple masking, which supports a well-controlled comparison. However, the primary endpoint was the surrogate measure of percent change in LDL-C at Week 24, and no primary outcome results have been posted, so whether the endpoint was met is unknown.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ebronucimab | SAL003 |
|---|---|---|
| LDL-C, % change | —Not posted · NCT05260411 | —Not posted · NCT07253584 |
| Non-HDL-C, % change | —Not posted · NCT05260411 | —Not posted · NCT07253584 |
| ApoB, % change | —Not posted · NCT05260411 | —Not posted · NCT07253584 |
| Lp(a), % change | —Not posted · NCT05260411 | —Not posted · NCT07253584 |
| 3-point MACE (% with event) | —Not posted · NCT05260411 | —Not posted · NCT07253584 |
LDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- SAL003
- —Not posted · NCT07253584
Non-HDL-C, % change
- Ebronucimab
- —Not posted · NCT05260411
- SAL003
- —Not posted · NCT07253584
ApoB, % change
- Ebronucimab
- —Not posted · NCT05260411
- SAL003
- —Not posted · NCT07253584
Lp(a), % change
- Ebronucimab
- —Not posted · NCT05260411
- SAL003
- —Not posted · NCT07253584
3-point MACE (% with event)
- Ebronucimab
- —Not posted · NCT05260411
- SAL003
- —Not posted · NCT07253584
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SAL003: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ebronucimab
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · SAL003's landscape